24/7 Wall St. » CRXL

Today’s Biggest Market Moves 9/17/2010 (RIMM)(ORCL)(ARNA)

247wallst — Fri, 17 Sep 2010 12:39:26 +0000

Research In Motion (NASDAQ: RIMM) is higher by 5% after strong earnings.

Oracle (NASDAQ: ORCL) is up 4% after posting good quarterly numbers.

Crucell (NASDAQ: CRXL) is up over 55% on news of a takeover offer from Johnson & Johnson (NYSE: JNJ)

Arena Pharma (NASDAQ: ARNA) is off 44% on new that the FDA rejected on of it most important trials.

Douglas A. McIntyre

Filed under: Market Open Tagged: ARNA, CRXL, JNJ, ORCL, RIMM

Top 10 Analyst Upgrades & Downgrades (CSCO, CRXL, ITW, LVS, NFLX, POT, PT, SUPM, WRI, XEL)

Administrator — Wed, 18 Aug 2010 12:07:26 +0000

These are some of this Wednesday’s top analyst calls with upgrades, downgrades, and initiations seen from Wall Street research firms:

Cisco Systems Inc. (NASDAQ: CSCO) Cut to Underperform at First Global.
Crucell NV (NASDAQ: CRXL) Cut to Neutral at UBS.
Illinois Tool Works Inc. (NYSE: ITW) Cut to Neutral at Goldman Sachs.
Las Vegas Sands Corp. (NYSE: LVS) Target Raised to $22 at Citigroup.
Netflix, Inc. (NASDAQ: NFLX) Cut to Underperform at Morgan Keegan.
Potash Corp. of Saskatchewan (NYSE: POT) Target raised to $170 at UBS; Traget Raised to $160 at CIBC; Credit Suisse raised Target to $150.
Portugal Telecom SA (NYSE: PT) Raised to Neutral at JPMorgan.
SuperMedia (NASDAQ: SUPM) Cut to Perform at Oppenheimer.
Weingarten Realty Investors Company (NYSE: WRI) Raised to Outperform at Wells Fargo.
Xcel Energy Inc. (NYSE: XEL) Started as Neutral at JPMorgan.

You can join our free daily email distribution list to hear more about dividend trends, analyst upgrades and downgrades, top day trader and active trader alerts, news on Buffett and other investment gurus, IPOs, secondary offerings, private equity, and more.

JON C. OGG

Filed under: General Tagged: CRXL, CSCO, ITW, LVS, NFLX, POT, PT, SUPM, WRI, XEL

Top 10 Analyst Upgrades and Downgrades (AEZS, AXP, ARTC, BRCD, GLW, CRXL, GS, IGT, MOT, TRA)

247wallst — Tue, 18 Aug 2009 11:53:29 +0000

These are ten of the top analyst research upgrades, downgrades, and initiations seen early this Tuesday morning with about two hours until the market opens:

Aeterna Zentaris (AEZS) Cut to Sector Perform at RBC; cut at Canaccord and at Desjardins also.
American Express (AXP) Raised to Outperform at KBW.
Arthrocare (ARTC) Raised to Buy at Canaccord.
Brocade (BRCD) Raised to Strong Buy at S&P.
Corning (GLW) Raised to Outperform at Oppenheimer.
Crucell (CRXL) Cut to Sell at ING.
Goldman Sachs (GS) Raised to Buy at Pali.
International Game Tech (IGT) Raised to Overweight at JPMorgan.
Motorola (MOT) Started as Buy at Canaccord.
Terra Industries (TRA) Started as Overweight at JPMorgan.

JON C. OGG
AUGUST 18, 2009

Posted in Analyst Calls Tagged: AEZS, ARTC, AXP, BRCD, CRXL, GLW, GS, IGT, MOT, TRA

Swine Flu Lessons from SARS, Mad Cow & Bird Flu of Past (GILD, BCRX, NVAX, GNBT, VICL, AVII, CRXL, RHHBY, GSK, SFD, EWW, MXF)

247wallst — Mon, 27 Apr 2009 11:40:00 +0000

Monday is looking like a SWINE FLU speculative flu stock stock bonanza, and we want to caution about some of the lessons of scares in the past of SARS, bird flu, Mad Cow, and even hoof & mouth as similar references. The two approved drug treatments, not vaccines, which are being released are Tamiflu made by Roche (OTC: RHHBY) and Relenza made by GlaxoSmithkline (NYSE: GSK). Gilead Sciences, Inc. (GILD) gets royalties from Roche for Tamiflu, and its shares are indicated north of $48.00 after a $45.80 close on Friday. There are also waves of tier-two and tier-three stocks which could move on this news, but be advised that we have seen these pops in the past from SARS and Bird Flu which were followed ultimately by lower share prices and many of the speculative players disappeared.

Of the tier-two stocks, you have BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) and Novavax, Inc. (NASDAQ: NVAX). Of the tier-three stocks you have Generex Biotechnology Corp. (NASDAQ: GNBT), Vical Inc. (NASDAQ: VICL), AVI Biopharma, Inc. (NASDAQ: AVII), and Crucell NV (NASDAQ: CRXL). More descriptive data has been provided for each move. On another scale, Smithfield Foods Inc. (NYSE: SFD), the iShares MSCI Mexico Investable Market Index (NYSE: EWW), and The Mexico Fund, Inc. (NYSE: MXF) have exposure here as well.

BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) was up big Friday as it is a maker of drugs that block key enzymes in viral diseases like the flu, shares are indicated over $3.00 after a $2.21 close on Friday. Novavax, Inc. (NASDAQ: NVAX) is another clinical stage company using its virus-like particle platform technology for flu treatments; stock is indicated north of $2.50 after closing up some 75% at $1.42 Friday.

Generex Biotechnology Corp. (NASDAQ: GNBT) is being passed around as a penny stock flu player with shares indicated around $0.40 after closing up 25% at almost $0.34 Friday. Vical Inc. (NASDAQ: VICL) closed up 3% Friday at $2.53 and shares are indicated up around $3.00. AVI Biopharma, Inc. (NASDAQ: AVII) rose over 20% to $0.89 Friday and shares are indicated up marginally as a result. Crucell NV (NASDAQ: CRXL) has a faster way of making flu vaccines. This closed up 1% on Friday and is hardly moving.

This could have an impact on food stocks and even an ETF and a closed-end fund that each track Mexico. Smithfield Foods Inc. (NYSE: SFD) is deemed as the big pork play among the U.S. food companies. There are also two plays on the fund side with a closed-end fund and an ETF. The iShares MSCI Mexico Investable Market Index (NYSE: EWW) may be taking a hard hit this morning because of the Mexico-tied swine flu being the source of the disease. There have been more than 1,300 suspected cases and roughly 100 deaths from swine flu. This is the key ETF that traders use to trade exposure to Mexico. The Mexico Fund, Inc. (NYSE: MXF) is a closed-end mutual fund that may also take a hard hit this morning because of the Mexico-tied swine flu being the source of the disease.

Those who believe that the sky is falling will point back to the flu scare of 1918 that decimated populations. Keep in mind that there was little communication and the treatment at the time was generally bed rest and no hygiene was practiced by the bulk of the population. You can probably bet that you will be hearing “squeal like a pig!” jokes sooner rather than later.

As a reminder, these huge gap-ups can last more than a day, but historically we have seen each successive move usually being less than the first. As with issues such as SARS and bird flu, the world did not end and it was only the SARS scare which actually caused real damage. We also had the great Mad Cow disease craze and even teh Hoof & Mouth scare, all of which created initial moves but ultimately had zero net impact on sectors and the economy as a whole.

JON C. OGG

Posted in Biotech, Drug companies, Food, Medical, Pharmaceuticals, Regulation, Research, Trading Alert Tagged: AVII, BCRX, CRXL, GILD, GNBT, GSK, NVAX, RHHBY, VICL

Top Pre-Market Analyst Upgrades (AXYS, CRXL, DFT, LVLT, LGND, NOC, OXGN, PFE)

247wallst — Thu, 12 Feb 2009 12:29:45 +0000

These are some of this morning’s top pre-market analyst upgrades and positive research calls from Wall Street this Thursday morning with over two hours until the market opens:

Axsys Technologies (AXYS) Raised to Overweight at JPMorgan.
Crucell (CRXL) Started as Buy at Jefferies.
DuPont Fabros Technology (DFT) Raised to Outperform at Wachovia.
Level 3 Communications (LVLT) Raised to Hold at Stanford.
Ligand Pharmaceuticals (LGND) Started as Buy at Merriman Curhan Ford.
Northrop Grumman (NOC) Raised to Outperform at Bernstein.
Oxigene (OXGN) Started as Buy at Merriman Curhan Ford.
Pfizer (PFE) Raised to Outperform at Leerink Swann.

Jon C. Ogg
February 12, 2009

Posted in Analyst Calls Tagged: analyst upgrades, AXYS, CRXL, DFT, independent research, LGND, LVLT, NOC, OXGN, PFE

Top Pre-Market Analyst Upgrades (MDRX, BDX, ED, CRXL, CSX, RTN, SGR, SNN)

247wallst — Fri, 09 Jan 2009 07:23:54 +0000

These are the early bird upgrades and positive analyst calls we have seen from Wall Street this Friday morning:

Allscripts-Misys (NASDAQ: MDRX) Raised to Outperform at William Blair.
Becton Dickinson (NYSE: BDX) Raised to Overweight at Morgan Stanley.
Consolidated Edison (NYSE: ED) Raised to Buy at Citigroup.
Crucell (NASDAQ: CRXL) Raised to Buy at RBS.
CSX (NYSE: CSX) Raised to Buy at Deutsche Bank.
Raytheon (NYSE: RTN) Raised to Buy at Goldman Sachs.
Shaw Group (NYSE: SGR) Cut to Hold at Citigroup.
Smith & Nephew (NYSE: SNN) Raised to Neutral at JPMorgan.

Jon C. Ogg
January 9, 2009

Posted in Analyst Calls Tagged: BDX, CRXL, CSX, ED, MDRX, RTN, SGR, SNN

Top 10 Early Bird Analyst Upgrades & Downgrades (BBBY, BTI, PAG, VRTX, MT, STD, CRXL, FMCN, MR, OWW)

247wallst — Wed, 12 Nov 2008 07:06:37 +0000

These are the ten early bird analyst upgrades and downgrades we have seen early this morning with two and a half hours until the market opens:

Bed Bath & Beyond Raised (BBBY) Raised to Neutral from Sell at Goldman Sachs.
British American Tobacco (BTI) Raised to Buy at Goldman Sachs.
Penske Automotive (PAG) Raised to Buy at Goldman Sachs.
Vertex Pharmaceuticals (VRTX) Started as Buy at piper Jaffray.
Arcelor Mittal (MT) Cut to Sell from Buy at5 Citigroup.
Banco Santander (STD) Cut to Underweight at JPMorgan.
Crucell (CRXL) Cut to Hold at ING.
Focus Media (FMCN) Downgraded at Citigroup and Goldman Sachs (likely others as well).
Mindray Medical International (MR) Downgraded at Citigroup and Goldman Sachs.
Orbitz Worldwide (OWW) Cut to Sell at Goldman Sachs.

Jon C. Ogg
November 12, 2008

Posted in Analyst Calls Tagged: BBBY, BTI, CRXL, FMCN, MR, MT, OWW, PAG, STD, VRTX

Biotech Business Daily (CHTP, CRXL, LLY, IOMI, MEDX, TRCA)

247wallst — Tue, 13 May 2008 12:10:21 +0000

Chelsea Therapeutics International, Ltd. (NASDAQ: CHTP) falling today after first quarter earnings showed wider losses than first quarter 2007. Net loss was $8.7 million compared to a loss of $3.8 million in 2007. The wider loss was driven primarily through increased research and development expenses. Shares are down $0.44, or 8%, at $4.69. The 52-week range is $4.45 to $8.41.

Crucell NV (NASDAQ: CRXL) up today after cutting its net loss in half, posting $13.2 million in losses. The company has $120 million in new contracts for pediatric vaccine Quinvaxem to look forward to in the next two years. Revenues are on track to meet guidance. Also, the company announced this morning that Phase II testing of rabies monoclonal antibody combination product will begin in the Philipines. The product has already commenced testing in the U.S. Shares are up over 8% at $19.43 in mid-day trading. The 52-week range is $12.76 to $24.81.

Eli Lilly & Co. (NYSE: LLY) announced a partnership with TopCoder today, allowing Eli Lilly to outsource complex drug discovery through complex technology processes to the software developer. Shares are down less than 1% at $47.82. The 52-week range is $46.60 to $60.00.

Iomai Corporation (NASDAQ: IOMI) is soaring to new highs today after receiving a $189 million offer yesterday from vaccine maker Intercell AG which trades on the Vienna exchange. The offer of $6.60 per share is a 126% premium to the closing share price Monday of $2.92. As a result of the acquisition, Intercell will have full rights to Iomai’s diarrhea vaccine set to enter Phase III trials in early 2009. Shares are up a whopping 116% at $6.33 in mid-day trading on extremely high relative trading volume. The 52-week range for the biotech company is $0.70 to $4.70.

Medarex Inc. (NASDAQ: MEDX) received a boost after the company was upgraded by Needham & Co. to "Buy" from "Hold." Shares are up $0.56, or almost 8%, at $7.59. The 52-week range is $6.88 to $ 18.23.

Tercica Inc. (NASDAQ: TRCA) dropping over 15% today after posting wider net losses yesterday. The endocrine health biotech company generated a net loss of $17.5 million for the quarter, compared to a net loss of $12.4 million in the first quarter of 2007. Shares down $0.77 at $4.22 in early morning trading. The 52-week range is $4.27 to $8.11.

Rachel Lopez
May 12, 2008